IDEAYA's rare cancer drug shows promise as company lays out Phase III plans [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Darovasertib, a protein kinase inhibitor C (PKC) being evaluated in neoadjuvant uveal melanoma (UM), has achieved a tumour shrinkage of at least 30% in around half of patients, and a 61% eye preservation rate following enucleation in interim data from a Phase II trial (NCT05907954). In step with the trial's interim results, US-based IDEAYA Biosciences has also concluded a successful Type C meeting with the US Food and Drug Administration (FDA), setting out the design for a pivotal trial of the drug. Incorporating guidance from the FDA meeting, IDEAYA said it projects the enrolment of approximately 400 patients in the randomised Phase III trial, with darovasertib in the treatment or control arm. The trial will enrol both patients eligible for enucleation and patients eligible for plaque brachytherapy. IDEAYA said that for the enucleation cohort, the randomisation will be with or without darovasertib as neoadjuvant therapy; and for the plaque brachytherapy cohort, the randomisati
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.MarketBeat
- IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerPR Newswire
- IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayPR Newswire
IDYA
Earnings
- 11/4/24 - Beat
IDYA
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IDYA's page on the SEC website